[1]王丽娟,刘芳芳,孙晓雯.左西孟旦联合盐酸伊伐布雷定治疗对慢性心力衰竭患者心功能、心肌纤维化标志物及运动耐量的影响[J].内科,2020,15(06):690-693.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.16]
 WANG Lijuan,LIU Fangfang,SUN Xiaowen.Effects of levosimendan combined with ivabradine hydrochloride on heart function, myocardial fibrosis markers and exercise tolerance in patients with chronic heart failure[J].Internal Medicine of China,2020,15(06):690-693.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2020.06.16]
点击复制

左西孟旦联合盐酸伊伐布雷定治疗对慢性心力衰竭患者心功能、心肌纤维化标志物及运动耐量的影响()
分享到:

《内科》[ISSN:1006-6977/CN:61-1281/TN]

卷:
15卷
期数:
2020年06
页码:
690-693
栏目:
论著
出版日期:
2020-12-31

文章信息/Info

Title:
Effects of levosimendan combined with ivabradine hydrochloride on heart function, myocardial fibrosis markers and exercise tolerance in patients with chronic heart failure
文章编号:
1673-7768(2020)06-0690-04
作者:
王丽娟刘芳芳孙晓雯
焦作市中站区人民医院心血管内科,河南省焦作市454191
Author(s):
WANG Lijuan LIU Fangfang SUN Xiaowen
Department of Cardiovascular Medicine, Jiaozuo Zhongzhan People′s Hospital, Jiaozuo 454191, Henan Province, China
关键词:
慢性心力衰竭左西孟旦盐酸伊伐布雷定心功能心肌纤维化运动耐量
Keywords:
Chronic heart failure Levosimendan Ivabradine hydrochloride Cardiac function Myocardial fibrosis Exercise tolerance
分类号:
R 541
DOI:
DOI:10.16121/j.cnki.cn45-1347/r.2020.06.16
文献标志码:
A
摘要:
目的探讨左西孟旦联合盐酸伊伐布雷定治疗对慢性心力衰竭患者心功能、心肌纤维化标志物及运动耐量的影响。方法选择2018年1月至2019年10月我院收治的慢性心力衰竭患者70例为研究对象,采用随机数字法分为两组,每组35例。对照组患者给予左西孟旦治疗,观察组患者给予左西孟旦及盐酸伊伐布雷定治疗,疗程14 d。比较两组患者的临床疗效、心肌纤维化标志物水平、运动耐量及心功能。结果治疗14 d后,观察组患者的治疗总有效率(94.3%)显著高于对照组(74.3%),结缔组织生长因子(CTGF)、Ⅰ型胶原交联羧基末端肽(ⅠCTP)、层连蛋白(LN)、透明质酸(HA)及Ⅲ型前胶原氨基末端肽(PⅢNP)水平均显著低于对照组,运动时间、运动当量、无氧阈值(AT)、峰值耗氧量(VO2max)长(大)于对照组,左心室射血分数(LVEF)显著高于对照组,B型脑钠肽(BNP)水平显著低于对照组,差异均有统计学意义(P<0.05)。结论左西孟旦联合盐酸伊伐布雷定治疗,可显著改善慢性心力衰竭患者的心功能,延缓患者心肌纤维化,提高患者的运动耐量。
Abstract:
ObjectiveTo investigate the effect of levosimendan combined with ivabradine hydrochloride on heart function, myocardial fibrosis markers and exercise tolerance in patients with chronic heart failure. MethodsA total of 70 patients with chronic heart failure admitted to our hospital from January 2018 to October 2019 were selected as the research subjects, and they were divided into two groups according to the random number method, with 35 cases in each group. The control group was treated with levosimendan, whereas patients in the observation group administrated levosimendan combined with ivabradine hydrochloride, for a fourteen-day treatment course. The clinical efficacy, levels of myocardial fibrosis markers, exercise tolerance and heart function were compared between the two groups. ResultsAfter a treatment of 14 days, compared with the control group, the observation group yielded a higher total effective rate of treatment (94.3% vs. 74.3%, P=0.022), lower levels in connective tissue growth factor (CTGF), carboxyterminal telopeptide of type Ⅰ collagen (ⅠCTP), laminin (LN), hyaluronic acid (HA) and N-terminal propeptide of type Ⅲ procollagen (PⅢNP), whereas longer or larger indicators in exercise time, exercise equivalence, anaerobic threshold (AT), and peak oxygen consumption (VO2max), a significantly higher left ventricular ejection fraction (LVEF), while a significantly lower B-type brain natriuretic peptide (BNP), with statistically significant differences (P<0.05). ConclusionLevosimendan combined with ivabradine hydrochloride in the treatment of patients with chronic heart failure can effectively improve cardiac function, delay myocardial fibrosis, and improve exercise tolerance in patients.

相似文献/References:

[1]李艳(综述) 罗恒(审校).慢性心力衰竭治疗及护理进展[J].内科,2015,(01):107.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.01.45]
 [J].Internal Medicine of China,2015,(06):107.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.01.45]
[2]张盛开.不同剂量硝酸甘油治疗慢性心力衰竭的疗效观察及不良反应分析[J].内科,2015,(02):169.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.02.10]
[3]金献萍.老年慢性心力衰竭患者症状管理研究进展[J].内科,2015,(03):374.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.03.39]
 [J].Internal Medicine of China,2015,(06):374.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.03.39]
[4]王晓燕.综合护理干预对老年慢性心力衰竭患者心理状况及治疗依从性的影响[J].内科,2015,(03):413.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.03.53]
 [J].Internal Medicine of China,2015,(06):413.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.03.53]
[5]梁德贤 李庆军 陈康荣.心衰超声指数对慢性心力衰竭的诊断及预后评估价值[J].内科,2015,(04):446.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.04.04]
 LIANG De-xian,LI Qing-jun,CHEN Kang-rong.Value of heart failure echocardiography index to the diagnosis and prognostic prediction of chronic heart failure[J].Internal Medicine of China,2015,(06):446.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.04.04]
[6]骆是文.卡托普利治疗慢性心力衰竭23例疗效观察[J].内科,2014,(04):446.
 [J].Internal Medicine of China,2014,(06):446.
[7]王丽梅 陈鸿 史继娥.缬沙坦联合依那普利治疗对慢性心力衰竭患者心功能及BNP水平的影响[J].内科,2015,(05):616.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.05.07]
 WANG Li-mei,CHEN Hong,SHI Ji-e.Effect of valsartan combined with enalapril on heart function and BNP level in patients with chronic heart failure[J].Internal Medicine of China,2015,(06):616.[doi:DOI:10.16121/j.cnki.cn45-1347/r.2015.05.07]
[8]欧世宁 毛志锋.慢 性 心 力 衰 竭 与 卒 中[J].内科,2013,(01):60.
 [J].Internal Medicine of China,2013,(06):60.
[9]王杨光 何文威 冯敏.服用阿托伐他汀对慢性心力衰竭患者血氨基末端脑钠素前体的影响[J].内科,2013,(02):129.
 [J].Internal Medicine of China,2013,(06):129.
[10]李文军.ACEI类药物治疗慢性心力衰竭的研究进展[J].内科,2011,(02):152.
 [J].Internal Medicine of China,2011,(06):152.

更新日期/Last Update: 2021-01-11